Written by: Meredith Paci Functional Health Coach

What are you afraid of is a question I come back to often, one I've been asking long before this year. I land on it during any day, week, or season that starts to feel discombobulated, when overwhelm creeps in and I can't even name what I'm overwhelmed about, let alone find a way through it. Answering it honestly does one of two things: it shrinks the thing down to a size I can actually deal with, or it shows me I had more control the whole time than the overwhelm was letting on.

I heard that same question again recently, in a course taught by Dr. Rachel Rubin, a urologist and sexual medicine specialist. It was the statement her entire talk was built around, and I actually laughed out loud sitting in that room, because the timing felt too on the nose to be a coincidence. She says it constantly to the prescribers in front of her, not to put them on the defensive, but because it's the fastest way to find out whether a clinical decision is coming from evidence or from discomfort. Sometimes the evidence hasn't caught up yet. Discomfort just yells louder than intuition.

Here's why the question works so well, in a course room or anywhere else. You cannot answer it honestly while still holding a position you don't actually believe. It doesn't let you hide behind a stated reason that isn't the real one.

One of our group mentorship coaches had a client, 50 years old, who went to her doctor to ask whether hormone therapy was even something worth discussing, for symptoms affecting her sleep, her mood, her ability to function. Her doctor told her she was too old.

50!.. FIFTY! I don't even care if she was 52. I don't care if she was 56. I don't even care if she was 66!!!

That sent me straight back to this question. What is that doctor actually afraid of? What  would justify telling a 50 year old woman, regardless of her medical history, that she'd aged out of a treatment option?  All I could come up with is that it is easier to hide behind the confidence of inaction, even if inaction was being led by fear as opposed to actual risk or evidence…this is when the idea of 'inaction' feels like it aligns with 'doing no harm' but in this case specifically it actually could be the opposite.

So let's answer her question, because "too old" gets said to women constantly, and inappropriately.

"Too old" isn't a diagnosis

It's not a lab value. It's not a line on a chart where risk crosses over into certainty. When a clinician says it, what they usually mean is some version of "I was trained to be cautious past a certain age and I haven't revisited why," which is a very different statement than "the evidence shows this is unsafe for you."

Those two things get treated as the same sentence constantly, and they are not the same sentence. One is a clinical judgment made on your specific case. The other is a category, applied to every woman standing in front of that doctor regardless of what she's actually presenting with, what formulation is being discussed, or what her individual risk profile looks like. "Too old for hormone therapy" said as a blanket statement is a category error before it's anything else, because it treats hormone therapy as one thing. It isn't. Oral estradiol, transdermal estradiol, vaginal estradiol, progesterone, DHEA and testosterone are different molecules, different routes, different risk profiles, and lumping them into a single yes-or-no verdict is where a lot of bad counseling starts.

What's actually driving the caution after 60, or 10 years out

I want to be precise here, because there is real data behind age-related caution in hormone therapy, and I don't want to overcorrect into pretending it doesn't exist. It does. I just think it gets applied with far more certainty than the data itself supports.

The 2022 NAMS position statement is the reference point most clinicians are working from. It states that for women under 60, or within 10 years of menopause onset, without contraindications, the benefit-risk ratio is favorable for treating vasomotor symptoms and preventing bone loss. Past that window, NAMS describes the ratio as "less favorable," attributing it to greater absolute risk of coronary heart disease, stroke, VTE, and dementia. This is what's sometimes called the timing hypothesis, and it's also reflected in the American Heart Association's 2020 statement and a 2023 review from the American College of Cardiology published in Circulation.

WAIT! I want you to slow down with me, because this part tends to get flattened into "risk goes up, full stop," and that's not what the data says.

The risk stratification NAMS and AHA are citing comes heavily from the Women's Health Initiative (WHI), a great study that has been horribly misinterpreted. The WHI which studied one specific regimen: oral conjugated equine estrogen plus medroxyprogesterone acetate (a progestin not progesterone), at a fixed dose, in women with an average age in the early 60s. That's not the regimen most clients now are on. NAMS itself acknowledges that transdermal routes and individualized doses may lower the risk of VTE and stroke compared to oral ...yet oral is not 'bad'. What hasn't been done, to my knowledge, is a large age-stratified RCT specifically isolating late initiators on modern transdermal, or injectable, physiologically dosed estradiol the way WHI isolated oral CEE. This is a canyon sized gap that I am super confident will be closed over time.

It's also worth knowing that WHI actually ran a second arm, estrogen alone, no progestin, in women who'd had a hysterectomy. That arm told a different story than the combined one. In women aged 50 to 59 at the start, estrogen alone was associated with a real reduction in coronary heart disease, somewhere in the range of 40 to 44% in subgroup analyses, along with meaningfully less coronary artery calcification years later. That's not a neutral safety finding. That's incredibly positive! It's also not something you can extend to the combined regimen. But it proves the point on its own: even within the one trial everyone cites for caution, timing and formulation moved the outcome in opposite directions. The same trial that gets summarized as "hormone therapy raises risk" also contains a subgroup where it lowered it.

It means the position is "the data we have on age and initiation timing comes from a narrower slice of hormone therapy than the general overall warning implies," not "we've proven that starting later on any formulation carries this same risk."

I believe that distinction gets lost constantly, and distinction is the difference between individualized caution and a blanket rule.

There's a second piece worth mentioning, and it goes back to the question 'what are you afraid of".

A huge amount of the hesitation clinicians carry around hormone therapy traces back to breast cancer risk. But that risk signal is not merely a property of estrogen itself. The increased breast cancer signal in WHI came from the combined estrogen-progestin arm, using synthetic MPA. The estrogen-alone arm, studied in women post-hysterectomy, showed no increase, and some follow-up data has suggested a reduction. 

I'd like to frame this differently...but I'll say upfront it isn't a controlled one: pregnancy involves estradiol levels in the thousands, dramatically higher than anything used in hormone therapy, and nobody counsels women out of pregnancy over cancer risk. In fact, breast cancer risk goes down! The physiology isn't identical, pregnancy estrogen comes with progesterone at extremely high levels alongside it, so it isn't the unopposed exposure that's the actual concern in someone with a uterus on estrogen therapy. I'm not presenting it as equivalent. I'm presenting it because the fear response to estradiol itself, independent of dose or context, tends to be disproportionate to what the physiology actually shows, and pregnancy is the clearest example of that disproportion sitting in plain sight.

So when a 50-year-old woman is told she's too old, ask what's actually being applied to her case. Is it her individual risk profile, her formulation, her route, her personal history? Or is it a category-level fear, inherited from a regimen she isn't even being offered?

If age were a real, evidence-based contraindication to hormone therapy generally, vaginal estrogen would be the hardest case to explain, because the data runs in the opposite direction.

Vaginal estrogen treats genitourinary syndrome of menopause locally, with minimal systemic absorption (not zero), which is why its risk profile doesn't carry the same cardiovascular and clotting concerns that drive the systemic timing hypothesis. The AUA/CUA/SUFU 2025 guideline, reaffirmed and strengthened in a September 2025 amendment, recommends vaginal estrogen for peri- and postmenopausal women with recurrent UTIs.

And the outcome data is not small. A 2025 study presented at the AUA annual meeting, using Epic Cosmos data across more than 2 million patient records, found that women over 55 with recurrent UTIs on vaginal estrogen had a sepsis rate of 10.6%, compared to 19.4% in women not using it, and a mortality rate of 0.42% versus 1.54%. A larger 2026 study published in Urology, covering nearly 1.9 million women, found the same protective pattern held across age groups, not just in older women.

Sit with that.

The intervention being withheld from a 50-year-old under a "too old" framing is the same category of treatment that, in a different formulation, measurably reduces sepsis and death in older women. If age were the disqualifying factor the "too old" comment implies, this data wouldn't exist. Here me well...age isn't the reason to withhold hormone therapy. In the case of vaginal estrogen specifically, age is often the reason to prescribe it! 

The client we discussed on that group mentorship call is 50! 

She is within the window NAMS itself describes as favorable for systemic therapy, assuming no individual contraindications her doctor hasn't disclosed. And if the conversation had been about vaginal estrogen for genitourinary symptoms, age wouldn't be a limiting factor at all. It might be the reason to start.

If you've been told you're too old, the question worth asking your provider isn't "are you sure." It's "too old for what, specifically, and based on what data." Most of the time, that question is where the real conversation finally starts.

If you're a coach and you want in on a group mentorship built to actually train you at this level, please reach out ...women need more of you and you need to be ready! 

If you want something more direct, we also do 1:1 strategy sessions.

[Contact us about group mentorship] · [Inquire about 1:1 strategy sessions]

And if a woman you know has been told she's too old, forward her this.

If you have a question of your own, the anonymous form that started this entire series is still open. Ask Fortify {HERE} I already have the next one queued up and I cannot wait to get into it!

Meredith Paci is the co-founder of Fortify Health Coaching. I am not a licensed medical provider. The content in this post is educational and does not constitute medical advice or a patient-provider relationship. If you are considering hormone therapy, work with a qualified and well experienced provider who will assess your individual history.